J. Casal Rubio

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 335 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience

Ma Carmen Areses Manrique, Joaquín Mosquera, Jorge García et al. · Translational Lung Cancer Research · 2018 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.

Mariano Provencio, Ernest Nadal, Amelia Insa et al. · Journal of Clinical Oncology · 2019 · 61 citations

Medicine, Oncology, Surgery +17

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

J. Casal Rubio, Francisca Vázquez, Margarita Amenedo et al. · Cancer Chemotherapy and Pharmacology · 2009 · 13 citations

Medicine, Oncology, Pharmacology +13

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

J. Casal Rubio, José Luis Fírvida-Pérez, Martín Lázaro-Quintela et al. · Cancer Chemotherapy and Pharmacology · 2013 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17